Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -13.76% | 9.47% | -5.43% | -16.92% | 25.61% |
| Gross Profit | 13.76% | -11.04% | -105.15% | -14.24% | -41.40% |
| SG&A Expenses | 21.36% | -1.48% | -3.55% | -7.02% | 5.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.56% | 7.06% | -5.70% | -15.20% | 21.49% |
| Operating Income | 7.56% | -8.25% | -168.39% | -9.47% | -33.35% |
| Income Before Tax | 3.98% | -7.89% | -154.00% | 7.27% | -21.04% |
| Income Tax Expenses | 126.67% | -- | -- | -- | 600.00% |
| Earnings from Continuing Operations | 3.95% | -7.89% | -154.00% | 7.27% | -21.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.95% | -7.89% | -154.00% | 7.27% | -21.07% |
| EBIT | 7.56% | -8.25% | -168.39% | -9.47% | -33.35% |
| EBITDA | 6.31% | -8.37% | -166.36% | -17.44% | -36.58% |
| EPS Basic | 21.93% | 12.36% | -143.83% | 15.26% | -16.37% |
| Normalized Basic EPS | 29.63% | 12.35% | -143.84% | 1.45% | -31.86% |
| EPS Diluted | 21.93% | 12.36% | -145.38% | 15.26% | -16.37% |
| Normalized Diluted EPS | 29.63% | 12.35% | -145.08% | 1.45% | -31.86% |
| Average Basic Shares Outstanding | 23.03% | 23.11% | 23.19% | 9.43% | 4.04% |
| Average Diluted Shares Outstanding | 23.03% | 23.11% | 19.80% | 9.43% | 4.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
